

Ombretta Turriziani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/670218/publications.pdf>

Version: 2024-02-01

99
papers

2,615
citations

279798

23
h-index

214800

47
g-index

100
all docs

100
docs citations

100
times ranked

4818
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytokine storm and histopathological findings in 60 cases of COVID-19-related death: from viral load research to immunohistochemical quantification of major players IL-1 β , IL-6, IL-15 and TNF- α . <i>Forensic Science, Medicine, and Pathology</i> , 2022, 18, 4-19.	1.4	37
2	External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy. <i>Scientific Reports</i> , 2022, 12, 3291.	3.3	4
3	(Auto)Antibody Responses Shape Memory NK Cell Pool Size and Composition. <i>Biomedicines</i> , 2022, 10, 625.	3.2	0
4	Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-centre experience and review of the literature.. <i>New Microbiologica</i> , 2022, 45, 62-72.	0.1	3
5	Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2022, 41, 2755-2763.	2.2	6
6	High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19. <i>Clinical Immunology</i> , 2022, 241, 109068.	3.2	5
7	Analysis of viral nucleic acids in duodenal biopsies from adult patients with celiac disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 1107-1110.	1.6	4
8	SARS-CoV-2 presence in seminal fluid: Myth or reality. <i>Andrology</i> , 2021, 9, 23-26.	3.5	54
9	SARS-CoV-2 diagnostics in the virology laboratory of a University Hospital in Rome during the lockdown period. <i>Journal of Medical Virology</i> , 2021, 93, 886-891.	5.0	12
10	Sperm cryopreservation during the SARS-CoV-2 pandemic. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1091-1096.	3.3	17
11	The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study). <i>Journal of Medical Virology</i> , 2021, 93, 4319-4325.	5.0	20
12	Molecular diagnosis of SARS-CoV-2 in seminal fluid. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2675-2684.	3.3	23
13	Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19). <i>Virus Research</i> , 2021, 295, 198283.	2.2	26
14	Asymptomatic individuals positive for anti-SARS-CoV-2 antibodies negative on molecular swab. <i>Lancet Microbe</i> , The, 2021, 2, e178.	7.3	2
15	Dolutegravir-Based Regimen for Maintenance of Viral Suppression in People Living with HIV: 48-Week Results in Real-Life Setting. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 478-485.	1.1	5
16	K1 and WU Polyomavirus in Respiratory Samples of SARS-CoV-2 Infected Patients. <i>Microorganisms</i> , 2021, 9, 1259.	3.6	3
17	Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 100, 115347.	1.8	36
18	CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats. <i>Journal of Virology</i> , 2021, 95, e0135821.	3.4	13

#	ARTICLE	IF	CITATIONS
19	The Synergistic Effect of Time of Exposure, Distance and No Use of Personal Protective Equipment in the Determination of SARS-CoV-2 Infection: Results of a Contact Tracing Follow-Up Study in Healthcare Workers. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9456.	2.6	3
20	Comparison of FTD SARS-CoV-2 Assay and RealStar RT-PCR kit 1.0 for the detection of SARS-CoV-2. <i>Journal of Virological Methods</i> , 2021, 298, 114276.	2.1	4
21	Chest computed tomography score, cycle threshold values and secondary infection in predicting COVID-19 mortality. <i>New Microbiologica</i> , 2021, 44, 145-154.	0.1	2
22	Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experience. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 298-303.	2.2	13
23	Comparative analysis of 2 commercial molecular tests for the detection of gastroenteric viruses on stool samples. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114893.	1.8	7
24	Detection of SARS-COV N2 Gene: Very low amounts of viral RNA or false positive?. <i>Journal of Clinical Virology</i> , 2020, 133, 104660.	3.1	27
25	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112696.	5.5	10
26	SARS-CoV-2 infection: diagnostic testing results occasionally require special attention. <i>Emerging Microbes and Infections</i> , 2020, 9, 1955-1957.	6.5	2
27	Anosmia and Ageusia as Predictive Signs of COVID-19 in Healthcare Workers in Italy: A Prospective Case-Control Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2870.	2.4	27
28	Type I interferons can be detected in respiratory swabs from SARS-Cov-2 infected patients. <i>Journal of Clinical Virology</i> , 2020, 128, 104450.	3.1	10
29	Seroprevalence of group B Coxsackieviruses: Retrospective study in an Italian population. <i>Journal of Medical Virology</i> , 2020, 92, 3138-3143.	5.0	9
30	Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. <i>European Radiology</i> , 2020, 30, 6808-6817.	4.5	530
31	High HIV-1 diversity in immigrants resident in Italy (2008–2017). <i>Scientific Reports</i> , 2020, 10, 3226.	3.3	8
32	Study of SARS-CoV-2 in semen and urine samples of a volunteer with positive naso-pharyngeal swab. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1819-1822.	3.3	207
33	A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 211-213.e4.	2.9	275
34	Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators. <i>Journal of Virology</i> , 2019, 93, .	3.4	16
35	Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success. <i>Journal of Clinical Virology</i> , 2019, 117, 61-67.	3.1	24
36	Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. <i>Sexually Transmitted Infections</i> , 2019, 95, 619-625.	1.9	18

#	ARTICLE	IF	CITATIONS
37	Increased expression of IL-32 correlates with IFN- γ , Th1 and Tc1 in virologically suppressed HIV-1-infected patients. <i>Cytokine</i> , 2019, 120, 273-281.	3.2	12
38	Copy-Years Viremia and Risk of Virological Failure in Long-Term Treated HIV Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 423-428.	2.1	3
39	Increased SAMHD1 transcript expression correlates with interferon-related genes in HIV-1-infected patients. <i>Medical Microbiology and Immunology</i> , 2019, 208, 679-691.	4.8	7
40	Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIV-infected patient. <i>Hematological Oncology</i> , 2019, 37, 176-184.	1.7	9
41	Antiviral Activity of Fecal Water Samples from HIV-1 Infected Subjects Treated with a Specific Probiotic Formulation. <i>Current HIV Research</i> , 2019, 17, 183-189.	0.5	1
42	Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming. <i>Frontiers in Immunology</i> , 2018, 9, 1031.	4.8	22
43	Consolidation of molecular testing in clinical virology. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 387-400.	4.4	12
44	Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 10, 106-112.	2.2	17
45	Dolutegravir-based regimen maintains virological success in a patient with archived mutations to integrase inhibitors. <i>Aids</i> , 2017, 31, 1900-1901.	2.2	1
46	Infectious Agents in Atherosclerotic Cardiovascular Diseases through Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2459.	4.1	35
47	Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns. <i>BMC Infectious Diseases</i> , 2017, 17, 581.	2.9	34
48	Lack of association of Chlamydia pneumoniae with cardiovascular diseases in virologically suppressed HIV patients. <i>New Microbiologica</i> , 2017, 40, 33-37.	0.1	1
49	Dominant enrichment of phenotypically activated CD38 ⁺ HLA-DR ⁺ CD8 ⁺ T cells, rather than CD38 ⁺ HLA-DR ⁺ CD4 ⁺ T cells, in HIV/HCV coinfecting patients on antiretroviral therapy. <i>Journal of Medical Virology</i> , 2016, 88, 1347-1356.	5.0	5
50	IFN-stimulated gene expression is independent of the IFNL4 genotype in chronic HIV-1 infection. <i>Archives of Virology</i> , 2016, 161, 3263-3268.	2.1	3
51	Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients. <i>Journal of Clinical Virology</i> , 2016, 76, 20-23.	3.1	4
52	Comparative Analysis of Real-Time Polymerase Chain Reaction Methods to Typing HLA-B*57:01 in HIV-1-Positive Patients. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 654-657.	1.1	7
53	First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing. <i>Journal of Clinical Virology</i> , 2016, 78, 1-3.	3.1	4
54	ISG15 expression correlates with HIV-1 viral load and with factors regulating T cell response. <i>Immunobiology</i> , 2016, 221, 282-290.	1.9	32

#	ARTICLE	IF	CITATIONS
55	Evaluation of performances of VERSANT HCV RNA 1.0 assay (kPCR) and Roche COBAS AmpliPrep/COBAS TaqMan HCV test v2.0 at low level viremia. <i>New Microbiologica</i> , 2016, 39, 224-227.	0.1	5
56	An epidemiological investigation to reconstruct a probable human immunodeficiency virus -1 transmission network: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 253.	0.8	0
57	Probiotics Reduce Inflammation in Antiretroviral Treated, HIV-Infected Individuals: Results of the "Probio-HIV" Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0137200.	2.5	120
58	Trends in drug resistance-associated mutations in a real-life cohort of Italian patients infected with HIV-1. <i>Journal of Global Antimicrobial Resistance</i> , 2015, 3, 267-272.	2.2	7
59	HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy. <i>Journal of Medical Virology</i> , 2015, 87, 315-322.	5.0	8
60	Dynamics of HIV DNA and Residual Viremia in Patients Treated With a Raltegravir-Containing Regimen. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, e18-e20.	2.1	4
61	Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization. <i>New Microbiologica</i> , 2015, 38, 531-40.	0.1	1
62	Detection and quantification of EBV, HHV-6 and CMV DNA in the gastrointestinal tract of HIV-positive patients. <i>Infection</i> , 2014, 42, 1033-1037.	4.7	10
63	Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients. <i>Medical Microbiology and Immunology</i> , 2014, 203, 207-16.	4.8	20
64	Early collection of saliva specimens from Bell's palsy patients: Quantitative analysis of HHV-6, HSV-1, and VZV. <i>Journal of Medical Virology</i> , 2014, 86, 1752-1758.	5.0	25
65	V3 Net Charge: Additional Tool in HIV-1 Tropism Prediction. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1203-1212.	1.1	8
66	Infectious burden and atherosclerosis: A clinical issue. <i>World Journal of Clinical Cases</i> , 2014, 2, 240.	0.8	83
67	Analysis of intracellular human immunodeficiency virus (HIV)-1 drug resistance mutations in multi-failed HIV-1-infected patients treated with a salvage regimen: 72-week follow-up. <i>Clinical Microbiology and Infection</i> , 2013, 19, E318-E321.	6.0	6
68	Short Communication: Analysis of the Integrase Gene from HIV Type 1-Positive Patients Living in a Rural Area of West Cameroon. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1729-1733.	1.1	11
69	Antiviral therapy: old and current issues. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 95-102.	2.5	62
70	Expression of the mRNA Levels for MDR1, MRP1, MRP4, and MRP5 IN HIV Antiretroviral Naive Patients: Follow-up at 48 Weeks After the Beginning of Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e54-e56.	2.1	3
71	Interferon-Induced Gene Expression in Cervical Mucosa during Human Papillomavirus Infection. <i>International Journal of Immunopathology and Pharmacology</i> , 2011, 24, 217-223.	2.1	13
72	Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1518-1524.	6.0	23

#	ARTICLE	IF	CITATIONS
73	Mutational Resistance Pattern of HIV Type 1 in CD14 ⁺ Monocytes, CD4 ⁺ T Cells, and Plasma from Treated Patients. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 625-634.	1.1	6
74	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010, 33, 195-206.	0.1	35
75	Non-Steroidal Anti-Inflammatory Drugs Increase the Antiretroviral Activity of Nucleoside Reverse Transcriptase Inhibitors in HIV Type-1-Infected T-Lymphocytes: Role of Multidrug Resistance Protein 4. <i>Antiviral Therapy</i> , 2009, 14, 1101-1112.	1.0	18
76	Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2008, 80, 766-771.	5.0	38
77	Study of the Genotypic Resistant Pattern in HIV-Infected Women and Children from Rural West Cameroon. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 781-785.	1.1	13
78	Genotypic Resistance of Archived and Circulating Viral Strains in the Blood of Treated HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 518-524.	2.1	35
79	The Effects of Prolonged Treatment with Zidovudine, Lamivudine, and Abacavir on a T-Lymphoblastoid Cell Line. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 960-967.	1.1	3
80	Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naïve HIV-infected patients. <i>Aids</i> , 2005, 19, 473-479.	2.2	14
81	Lack of Reduction of Thymidine Kinase Activity in Stavudine-Treated HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 701-703.	1.1	2
82	Host factors and efficacy of antiretroviral treatment. <i>New Microbiologica</i> , 2004, 27, 63-9.	0.1	8
83	Cellular issues relating to the resistance of HIV to antiretroviral agents. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 45-48.	1.5	4
84	P-Glycoprotein Expression by Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients Is Independent from Response to Highly Active Antiretroviral Therapy. <i>Vaccine Journal</i> , 2003, 10, 191-192.	3.1	5
85	Impaired 2'-deoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. <i>Biochemical Journal</i> , 2002, 368, 325-332.	3.7	29
86	Selection of a T-Cell Line Resistant to Stavudine and Zidovudine by Prolonged Treatment with Stavudine. <i>Antiviral Therapy</i> , 2002, 7, 105-111.	1.0	2
87	Decay of HIV Type 1 DNA and Development of Drug-Resistant Mutants in Patients with Primary HIV Type 1 Infection Receiving Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1599-1604.	1.1	17
88	May the Drug Transporter P Glycoprotein Affect the Antiviral Activity of Human Immunodeficiency Virus Type 1 Proteinase Inhibitors?. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 473-474.	3.2	17
89	Cellular factors involved in the induction of resistance of HIV to antiretroviral agents. <i>International Journal of Antimicrobial Agents</i> , 2000, 16, 353-356.	2.5	18
90	Correlation of Interferon-Induced Expression of MxA mRNA in Peripheral Blood Mononuclear Cells with the Response of Patients with Chronic Active Hepatitis C to IFN-alpha Therapy. <i>Journal of Interferon and Cytokine Research</i> , 1999, 19, 243-251.	1.2	66

#	ARTICLE	IF	CITATIONS
91	Anti-HIV antiviral activity of stavudine in a thymidine kinase-deficient cellular line. <i>Antiviral Therapy</i> , 1998, 3, 191-4.	1.0	1
92	Anti-HIV Antiviral Activity of Stavudine in a Thymidine Kinase-Deficient Cellular Line. <i>Antiviral Therapy</i> , 1998, 3, 191-194.	1.0	11
93	Further Study of the Mechanism Underlying the Cellular Resistance to AZT. <i>Biochemical and Biophysical Research Communications</i> , 1996, 228, 797-801.	2.1	11
94	Long-Term Exposure to Zidovudine Affects in Vitro and in Vivo the Efficiency of Phosphorylation of Thymidine Kinase. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 223-228.	1.1	73
95	Alteration of thymidine kinase activity in cells treated with an antiviral agent. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 1995, 9, 47-51.	0.7	5
96	Drug Combination of AZT and ddI: Synergism of Action and Prevention of Appearance of AZT-Resistance. <i>Antiviral Chemistry and Chemotherapy</i> , 1994, 5, 51-55.	0.6	9
97	Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. <i>Acta Virologica</i> , 1994, 38, 297-8.	0.8	15
98	<i>In vitro</i> Selection of Human Immunodeficiency Virus Type 1 Resistant to Ro 31-8959 Proteinase Inhibitor. <i>Antiviral Chemistry and Chemotherapy</i> , 1993, 4, 329-333.	0.6	30
99	Prostaglandin A inhibits replication of human immunodeficiency virus during acute infection. <i>Journal of General Virology</i> , 1991, 72, 2797-2800.	2.9	48